Naeije Robert
Department of Pathophysiology, Erasme Campus CP 604, Lennik Road, 808, B-1070, Brussels, Belgium.
Proc Am Thorac Soc. 2005;2(1):20-2. doi: 10.1513/pats.200407-037MS.
Pulmonary hypertension is a common complication of chronic obstructive pulmonary disease (COPD). The increase in pulmonary artery pressures is often mild to moderate. However, 5-10% of patients with advanced COPD may suffer from severe pulmonary hypertension and present with a progressively downhill clinical course because of right heart failure added to ventilatory handicap. The prevalence of clinically significant severe pulmonary hypertension in COPD is roughly estimated to be of 1-2/1,000. The cause of pulmonary hypertension in COPD is generally assumed to be hypoxic pulmonary vasoconstriction leading to permanent medial hypertrophy. However, recent pathologic studies point rather at extensive remodeling of all layers of the pulmonary arterial walls. These aspects account for minimal reversibility with supplemental oxygen. There may be a case for pharmacologic treatment of pulmonary hypertension in selected patients with advanced COPD and right heart failure. However, it will be a challenge for randomized controlled trials to overcome the difficulties of the diagnosis of right ventricular failure and the definition of a relevant primary endpoint in pulmonary hypertensive patients with COPD.
肺动脉高压是慢性阻塞性肺疾病(COPD)的常见并发症。肺动脉压力升高通常为轻度至中度。然而,5%至10%的重度COPD患者可能患有严重的肺动脉高压,并由于合并右心衰竭导致通气障碍而呈现出逐渐恶化的临床病程。COPD中具有临床意义的严重肺动脉高压的患病率大致估计为1至2/1000。COPD中肺动脉高压的病因通常被认为是低氧性肺血管收缩导致永久性中层肥厚。然而,最近的病理学研究更倾向于指出肺动脉壁各层的广泛重塑。这些因素导致补充氧气后可逆性极小。对于部分重度COPD合并右心衰竭的患者,可能有必要进行肺动脉高压的药物治疗。然而,随机对照试验要克服诊断右心室衰竭的困难以及定义COPD肺动脉高压患者相关主要终点的难题将是一项挑战。